Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-01 · accession 0001439222-26-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2026-03-02 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $0.00 | +13.7K | 68.8K | +25% | $0 |
| DM | 2026-03-03 | 2026-03-02 | AGIO | Gheuens Sarah | Chief Medical Off | S - Sale+OE | $28.96 | -4,055 | 67.6K | -6% | -$117.4K |
| DM | 2026-03-03 | 2026-03-01 | AGIO | Gheuens Sarah | Chief Medical Off | A - Grant | $0.00 | +88.0K | 14.0K | New | $0 |
| DM | 2026-03-03 | 2026-03-02 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $0.00 | -13.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2026-03-02 | M | A | 4,000 | $0.00 | 75,593 | D | — | — | |
| 2 | Common | Common stock | 2026-03-02 | S | D | 1,187 | $28.96 | 74,406 | D | — | — | |
| 3 | Common | Common stock | 2026-03-02 | S | D | 1,681 | $28.96 | 71,593 | D | — | — | |
| 4 | Common | Common stock | 2026-03-02 | M | A | 5,666 | $0.00 | 73,274 | D | — | — | |
| 5 | Common | Common stock | 2026-03-02 | S | D | 1,187 | $28.96 | 67,608 | D | — | — | |
| 6 | Common | Common stock | 2026-03-02 | M | A | 4,000 | $0.00 | 68,795 | D | — | — | |
| 7 | Derivative | Stock options (right to buy) | 2026-03-01 | A | A | 52,000 | $0.00 | 52,000 | D | $30.23 · — to 2036-03-01 | 52,000 Common stock | (F6) This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| 8 | Derivative | Restricted stock units | 2026-03-02 | M | D | 4,000 | $0.00 | 8,000 | D | — · — to — | 4,000 Common stock | (F4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F9) The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 9 | Derivative | Restricted stock units | 2026-03-02 | M | D | 5,666 | $0.00 | 5,667 | D | — · — to — | 5,666 Common stock | (F4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F8) The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 10 | Derivative | Restricted stock units | 2026-03-02 | M | D | 4,000 | $0.00 | 0 | D | — · — to — | 4,000 Common stock | (F4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F7) The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 11 | Derivative | Restricted stock units | 2026-03-01 | A | A | 22,000 | $0.00 | 22,000 | D | — · — to — | 22,000 Common stock | (F4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F5) The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 12 | Derivative | Restricted stock units | 2026-03-01 | A | A | 14,000 | $0.00 | 14,000 | D | — · — to — | 14,000 Common stock | (F4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F5) The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. |